

Provided by:



Allogeneic Stem Cell Transplantation Rounds 2018-2020

Response and Resistance to Selective FLT3 Inhibition in AML - 12/19/2019

December 19, 2019

1:00 PM - 2:00 PM

Target Audience

This program has been designed for Internal Medicine - Hematology, Internal Medicine - Medical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Identify and discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors. Patient selection will require consideration of many of these disease factors.
- 2 Describe the likelihood of developing *C. difficile* as well as methods to prevent transmission, the unique risks associated with this infection in transplant patients, and list methods that prevent infection including how practice changes effect outcomes.
- 3 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS, including an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches
- 4 Describe differences and potential risks and benefits associated with different donor choices from an interprofessional perspective with an emphasis on developing a consistent approach to donor selection through systematic evaluation of various options.

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Identify and discuss from an interprofessional perspective appropriate candidates for transplant based on many factors including infectious disease risks, comorbidity risks, disease specific risk factors. Patient selection will require consideration of many of these disease factors.
- 2 Describe the likelihood of developing *C. difficile* as well as methods to prevent transmission, the unique risks associated with this infection in transplant patients, and list methods that prevent infection including how practice changes effect outcomes.
- 3 Describe outcomes after allogeneic stem cell transplantation for patients with refractory AML or advanced MDS, including an outline of new treatment practices that may impact outcomes, and from an interprofessional perspective discuss availabilities of novel clinical trials and outcomes associated with new approaches

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For more information, please contact
Cherylann Lane, Olivia Hollister, Jazmin Tunstall
(215) 662-3181, (215) 954-3631, (215) 662-2862
cherylann.lane@uphs.upenn.edu, Olivia.Hollister@penmedicine.upenn.edu,
Jazmin.Tunstall@uphs.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of **1.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Cherylann Lane, None	Activity Coordinator	No Disclosure
Michelle Machamer, Other	Activity Coordinator	No Disclosure
David Porter, MD	Course Director	Holder of Intellectual Property Rights- Novartis AG-CAR T cells Grants/Research Support Recipient-Novartis AG-CAR T cells Spouse employment-Genentech, Inc.- N/A Advisor or Review Panel Member-Kite Pharm-CAR T cells Advisor or Review Panel Member-Incyte-GVHD Advisor or Review Panel Member-Bellicum-BMT Advisor or Review Panel Member-Novartis AG-CAR T cells Board Member-National Marrow Donor Program-Bone marrow transplant and cell therapy
Saar Gill, MD	Faculty Planner	Nothing to disclose
Jacqueline Smith, CRNP	Nurse Planner	Nothing to disclose
Noelle Frey, MD	Other Planning Committee Member	Husband Employer-Merck and Company, Inc.- Infectious Disease Consultant-Novartis AG- Oncology
Elizabeth Hexner, MD	Other Planning Committee Member	Nothing to disclose
Alison Loren, MSCE	Other Planning Committee Member	Nothing to disclose
Craig Freyer, PharmD	Pharmacy Planner	Nothing to disclose
Christine McMahon, MD	Faculty	Nothing to disclose

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected